China rejects Gilead’s patent for $1000-a-day drug – MarketWatch


MarketWatch
China rejects Gilead's patent for $1000-a-day drug
MarketWatch
China's government has rejected Gilead Sciences Inc.'s patent application for its controversial hepatitis C drug Sovaldi, but whether that really strikes a blow to the company's plans is up for debate. It was revealed Friday that China's State Intellectual Property …
Gilead Patent for its Sovaldi Hep C Drug is Rejected by Chinese AuthoritiesWall Street Journal (blog)


These Fortune 500 companies leapfrogged the restFortune
High cost of hepatitis drug reflects a broken pricing systemLos Angeles Times

all 79 news articles »

Write a Comment

Close